Is Aldeyra Therapeutics (ALDX) Stock Outpacing Its Medical Peers This Year?

Group 1 - Aldeyra Therapeutics, Inc. (ALDX) has shown a year-to-date return of 5.4%, outperforming the average return of 3.8% for the Medical sector [2][3] - The Zacks Consensus Estimate for ALDX's full-year earnings has increased by 66.3% over the past three months, indicating improved analyst sentiment and earnings outlook [2] - Aldeyra Therapeutics, Inc. is ranked 92 in the Zacks Industry Rank within the Medical - Drugs industry, which has seen an average loss of 7.5% this year, further highlighting ALDX's relative performance [3] Group 2 - Teva Pharmaceutical Industries Ltd. (TEVA) has achieved a year-to-date return of 61.7%, significantly outperforming both the Medical sector and its own industry [2][3] - The consensus EPS estimate for Teva has increased by 0.3% over the past three months, and it also holds a Zacks Rank of 2 (Buy) [3] - The Medical - Generic Drugs industry, to which Teva belongs, is currently ranked 56 and has experienced a positive movement of +10.5% this year [3]